http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
X60 고강도 저합금강의 미세조직 및 반복 변형거동에 미치는 합금 원소의 영향
김규식 ( Kyu Sik Kim ),김상식 ( Sang Shik Kim ),박광균 ( Kwang Kyun Park ),노경민 ( Kyoung Min Noh ),이기안 ( Kee Ahn Lee ) 대한금속재료학회(구 대한금속학회) 2013 대한금속·재료학회지 Vol.51 No.9
Repeated deformation behaviors of 10 different X60 based steels were investigated in this study. At room temperature, repeated deformation tests were conducted with f=0.2 Hz, sinusoidal wave form and Δεta (total strain amplitude) = 0.9%, which are conditions similar to those for coiled tubing application. Different alloys whose microstructures were varied with addition of alloying elements showed different fatigue life. In particular, X60 steel modified by addition of titanium had superior fatigue properties than the base X60 steel. To clarify the relationship between repeated deformation life and microstructure, morphologies of the fractured surfaces and crack propagation path were examined. Most of the cracks propagated smoothly along the ferrite-ferrite interface or through the ferrite, while the crack path was largely changed by pearlite phases, which were relatively harder phases than ferrite. Based on those results, we related the microstructure parameters to repeated deformation behavior.
전립선비대증의 치료로 Tamsulosin, Finasteride 병합요법시 투여 방법 및 증상호전에 따른 약물 순응도의 차이 분석
김규식(Kyu Shik Kim),정재훈(Jae Hoon Chung),김태효(Tae Hyo Kim),이기수(Ki Soo Lee),이승욱(Seung Wook Lee) 대한비뇨기종양학회 2015 대한비뇨기종양학회지 Vol.13 No.1
Purpose: It has been reported in several for factors on the drug compliance of patients, number of drug being taken, symptom, and pharmaceutical dosage form. However, Studies of drug compliance by dosing methodologies of tamsulosin, finasteride combination therapy and symptom relief for benign prostatic hyperplasia has not been performed. Therefore, we studied for symptom and differences in medication adherence in method of administration of tamsulosin, finasteride combination therapy. Materials and Methods: The groups were consisted in need of combination therapy of tamsulosin, finasteride on benign prostatic hyperplasia, one had packaged both drugs together (Group A, n=30) and the other were individually packaged both agents (Group B, n=30). International Prostatic Symptom Score (IPSS) were checked on first, 4weeks, and 8weeks. The evaluation was carried out of medicine compliance by checking the number of drugs 4weeks-interval. which was every 4weeks during 8weeks. Results: The properties other than the PSA in both groups, there was no statistically significant differences between patients. In first 4weeks, drug compliance of each Group A and B had tamsulosin 82.6%, 93.3% (p=0.033), finasteride 80.1%, 93.3% (p=0.042), and last 4weeks tamsulosin 80.6%, 93.7% (p=0.013), finasteride 79.5%, 93.7% (p=0.002) were checked. Group C, D had 81.4%, 96.4% (p=0.021) on 4weeks, 80.6%, 97.2% (p=0.011) on 8weeks. Conclusions: For co-administration of finasteride and tamsulosin are required in patients with benign prostatic hyperplasia, in order to enhance drug compliance, both tablets have to prescript together in one package to be taken at one time is useful.
만성 전립선염 / 만성 골반통증 증후군 치료법의 최신 경향
김규식(Kyu Shik Kim),이승욱(Seung Wook Lee) 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.1
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition; however, many of the traditional therapies like monotherapy used in clinical practice fail to show efficacy. There is no one particular treatment to be recommended as a mono-therapy for CP/CPPS. New concept of treatment which is `UPOINT" is introduced. The major barrier in treating men with CP/CPPS is the heterogenous nature of this syndrome. In order to treat appropriately patient should be evaluated individually to assess the nature of symptoms. To evaluate patients chronic urologic pelvic pain, six-point clinical phenotyping system is developed. The clinical domains are urinary symptoms, psychosocial dysfunction, organ-specific findings, infection, neurologic/systemic, and tenderness of muscles, which produces the acronym UPOINT. This clinical phenotyping system may provide a useful and clinically relevant framework for multimodal therapy for the treatment of CP/CPPS. However, concept of UPOINT needs randomization, placebo or sham control studies to show verified treatment.
정재훈(Jae Hoon Chung),김규식(Kyu Shik Kim),이승욱(Seung Wook Lee) 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.1
Purpose: Low quality research can have an error drawing result and it can be distored. Thus, quality assessment is required for appropriate clinical application of the results of studies using randomized controlled trial (RCT). Materials and Methods: A quality assessment was conducted on the articles of Prostate published in Republic of Korea, using typical tools of RCT quality analysis such as Jadad scale, van tulder scale, and Cochrane collaboration risk of bias Tool (CCRBT). Results: The first RCT about Benign prostatic hyperplasia is published in Korean journal of Urology at 1995 and 24 RCTs are publish since then. There were 2 RCTs in 90`s, 10 from 2001 to 2006, 12 from 2007 to 2012 and none in 2013. Five high quality analysis were found in Jadad scale and 8 were in van Tulder scale. Double blinding studies were done in 6 articles, and there was significant difference in quality weather performing double blinding or not. Conclusions: The number of RCT articles were increased over time. However, quality of RCT articles were vulnerable. In order to develop prostate studies, adequate randomization and blinding methods, IRB review, and financial support are required for the conduct of high quality randomized controlled trials.
만성전립선염 환자에서 다중중합효소연쇄반응을 이용해 검출된 미생물
이정우(Jeong Woo Lee),정재훈(Jae Hoon Chung),김규식(Kyu Shik Kim),박경식(Kyung Seek Park),이승욱(Seung Wook Lee) 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.2
Purpose: We aimed to identify the cryptic organism of the prostate in the chronic prostatitis patients by polymerase chain reaction. Materials and Methods: The polymerase chain reaction test had performed from 686 chronic prostatitis patients. The species of detected organisms from test was analyzed. Furthermore, the association between the species of organisms and the location of pain was analyzed. Results: The organisms had detected in about 80% of chronic prostatitis patients. Especially Gardnerella vaginalis showed the highest detection rate of chronic prostatitis patients (27.4%). The highest detection rate of organisms was shown in chronic prostatitis patients who had urethral pain (81.1%, p=0.016). And Chlamydia trachomatis showed the significant association with urethral pain (p=0.005). Conclusions: The organisms had detected by polymerase chain reaction in almost chronic prostatitis patients. And the association of the species of organisms and the pain location was shown.
신혈관근지방종의 치료로 시행한 선택적동맥색전술의 장기간 치료 효과 분석
정재훈(Jae Hoon Chung),문경현(Kyung Hyun Moon),김태효(Tae Hyo Kim),이기수(Ki Soo Lee),이완(Wan Lee),김규식(Kyu Shik Kim),이승욱(Seung Wook Lee) 대한비뇨기종양학회 2014 대한비뇨기종양학회지 Vol.12 No.3
Purpose: We evaluate the complication rates and the treatment outcome of patients treated by selective arterial embolization (SAE) for a large or symptomatic renal angiomyolipoma (AML). Materials and Methods: 52 patients with 56 kidneys containing AML were treated by SAE. All patients were treated by SAE and followed up in multicenter. The variables used for the analysis were age, gender, presence of tuberous sclerosis (TS), and maximal tumor size prior to SAE. The study end points were recurrence of symptoms or bleeding, the need for re-embolization or surgery, and disease-specific survival. The mean follow-up period for the entire group was 6.8 year. Results: Mean patient age was 51.4 year and the mean initial tumor size was 8.8cm. Successful SAE was achieved in 48 cases (84.8%) with minor complication rate of 11.5%. Avoidance of surgery was achieved in 91.9% of the kidneys in five years. And avoidance of re-embolization was achieved in 67.9% in five years. No retroperitoneal hemorrhage was noted during follow-up. Disease-specific survival of the entire cohort was 100%. Conclusions: SAE of renal AML has long-term efficacy in preventing hemorrhagic complications of renal AML, and preservation of the involved kidneys is amenable.
전립선비대증을 동반한 발기부전 환자에서 Mirodenafil 50mg 매일 복용요법과 100mg 필요 시 복용요법의 유효성 비교
조중훈(Jung Hoon Cho),서준상(Jun Sang Seo),김규식(Kyu Shik Kim),김태효(Tae Hyo Kim),노준화(Joon Hwa Noh),배재현(Jae Hyun Bae),오철영(Cheol Young Oh),이승환(Seung Hwan Lee),조성용(Sung Yong Cho),최재덕(Jae Duck Choi),한준현(Jun Hyun H 대한비뇨기종양학회 2015 대한비뇨기종양학회지 Vol.13 No.3
Purpose: To Compare the improvement of erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) as well as the efficacy of mirodenalfil 50mg once daily and 100mg on-demand in patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Materials and Methods: Prospective study was done with 220 patients who had BPH and ED from June 2013 to October 2014. Out of 220 individuals, 260 met inclusion criteria and 204 finished the research. Patients were divided into two groups. Group 1 had mirodenafil 50mg once daily and Group 2 had mirodenafil 100mg on-demand. The five-item version of the International Index of Erectile Function (IIEF-5), International Prostate Symptom Score (IPSS), Qmax, and residual urine volume(PVR) were assessed immediately before initiation of treatment (V1) and after four (V2) and twelve weeks of treatment (V3). Results: No difference of IIEF-5, IPSS, Qmax, and PVR between two groups in V1. At V3, both groups had improvements of IPSS and group 1 had better improvements (-5.1±4.4 vs. -3.1±3.9 p<0.001). And Group 1 had larger improvements than Group 2 in Qmax significantly. No difference in PVR in both groups comparing V1 vs. V2 and V1 vs V3. Group 1 had better improved IIEF-5 than Group 2 (V1 vs. V3 : 4.8±5.8 vs. 4.4±5.1; p=0.032). There was no drop out patients due to cardiovascular problems. Conclusions: Once daily mirodenafil 50mg was more efficacious in treating both ED and LUTS than on-demand dosing mirodenafil 100mg without any complication of cardiovascular problems.
전립선비대증의 치료로 Sildenafil과 Finasteride 병용요법의 안전성 및 유효성
이승욱(Seung Wook Lee),이승환(Seung Hwan Lee),김규식(Kyu Shik Kim),이석영(Seokyoung Lee),정재훈(Jae Hoon Chung) 대한비뇨기종양학회 2018 대한비뇨기종양학회지 Vol.16 No.2
Purpose: The 5-alpha reductase inhibitors (5ARI) are one of the most commonly used medications for the treatment of benign prostatic hyperplasia (BPH). Phosphodiesterase type-5 inhibitors are also used to treat BPH. 5ARI is a drug with adverse effects of sexual dysfunction. In this study, we investigated the safety and efficacy of coadministration of finasteride and sildenafil on sexual function and lower urinary symptoms in patients with BPH. Materials and Methods: We retrospectively reviewed the medical records of patients who were receiving finasteride and sildenafil daily regimens for treatment of BPH in 2 university hospitals. Patients with adverse effects, vital sign, physical exam, laboratory test, 5-item version of the international index of erectile function (IIEF-5), International Prostate Symptom Score (IPSS), quality of life (QoL) were analyzed. Results: The number of patients analyzed in this study was 218. The mean age of the patients was 62.63±8.37 years and the mean duration of medication was 18.23±10.97 weeks. Significant changes were not observed in the vital signs measured before and after the drug administration. Compared with before treatment, improvement of lower urinary tract symptom (IPSS: 17.56±4.21 vs. 11.64±5.33, p<0.001) was observed and improvement of sexual function (IIEF-5: 9.44±5.21 vs. 12.73±6.81, p<0.001) was also confirmed. Conclusions: Daily coadministration of finasteride and sildenafil for the treatment of BPH could be used safely, and improvement of lower urinary tract symptom as well as improvement of sexual function could be expected.